The pharmacodynamics of i.v. and subcutaneous (s.c.) tinzaparin sodium compared with heparin in healthy volunteers were studied. A randomized, open-label, five-treatment, five-period-crossover study ...

Only one study evaluating the efficacy and safety of tinzaparin for the treatment of DVT has been published. In a multicenter, randomized, double-blind trial by the American- Canadian Thrombosis Study ...

Review the side-effects of Tinzaparin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared ...

According to a new study published in JAMA, treatment with low molecular-weight heparin tinzaparin did not significantly reduce recurrent venous thromboembolism (VTE) or major bleeding and overall ...

The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Tinzaparin. This inhibition accounts ...

Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. Background: VTE is a major cause of morbidity ...

This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

Details concerning the Tinzaparin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

Please provide your email address to receive an email when new articles are posted on . Extended thromboprophylaxis with weight-adjusted tinzaparin appeared safe and effective for patients following ...

Please provide your email address to receive an email when new articles are posted on . The use of daily tinzaparin for 6 months did not significantly reduce recurrent venous thromboembolism, major ...